- IgA nephropathy in a patient with ankylosing spondylitis well controlled with etanercept
-
Do-Hyeong Lee, Geun-Tae Kim, Na-Kyoung Hwang, Eun-Heui Kim
-
Kosin Med J. 2018;33(1):85-90. Published online June 30, 2018
-
DOI: https://doi.org/10.7180/kmj.2018.33.1.85
-
-
1,879
View
-
8
Download
-
1
Citations
-
Abstract
PDFPubReader
Ankylosing spondylitis (AS) can involve the eye, gastrointestinal system, cardiopulmonary system, skin, kidneys, and spinal and peripheral joints. It is rarely accompanied by immunoglobulin A (IgA) nephropathy. Although IgA is involved in both AS and IgA nephropathy, the relationship between these diseases remains unclear. We detected hematuria and proteinuria in a 32-year-old male patient with ankylosing spondylitis that remained stable for 4 years through treatment with etanercept, a tumor necrosis factor-α (TNF-α) inhibitor, and diagnosed IgA nephropathy through a renal biopsy. IgA nephropathy seems to be less commonly associated with AS disease activity or specific treatment such as TNF-α inhibitor use.
-
Citations
Citations to this article as recorded by
- IgA Nephropathy—Ankylosing Spondylitis–Associated or Adalimumab-Induced?
Joana Ricardo Pires, Anabela Tavares Valadão Barcelos JCR: Journal of Clinical Rheumatology.2021; 27(8S): S449. CrossRef
|